Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600cxc

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS 7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS 8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS 9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS 10	SEP 22	DIPPR file reloaded
NEWS 11	DEC 08	INPADOC: Legal Status data reloaded
NEWS 12	SEP 29	DISSABS now available on STN
NEWS 13	OCT 10	PCTFULL: Two new display fields added
NEWS 14	OCT 21	BIOSIS file reloaded and enhanced
NEWS 15	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16	NOV 24	MSDS-CCOHS file reloaded
NEWS 17	DEC 08	CABA reloaded with left truncation
NEWS 18	DEC 08	IMS file names changed
NEWS 19	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 20	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus

NEWS EXPRESS	NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:19:35 ON 17 DEC 2003

=> file medline, agricola, caba, caplus, biosis, biotechno, uspatfull
COST IN U.S. DOLLARS SINCE FILE TOTAL

```
                                                        ENTRY     SESSION
FULL ESTIMATED COST                                      0.42        0.42

FILE 'MEDLINE' ENTERED AT 13:20:45 ON 17 DEC 2003

FILE 'AGRICOLA' ENTERED AT 13:20:45 ON 17 DEC 2003

FILE 'CABA' ENTERED AT 13:20:45 ON 17 DEC 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 13:20:45 ON 17 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:20:45 ON 17 DEC 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 13:20:45 ON 17 DEC 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'USPATFULL' ENTERED AT 13:20:45 ON 17 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (schroeder, j? or schroeder j?)/au
L1         4908 (SCHROEDER, J? OR SCHROEDER J?)/AU

=> s (pei, z? or pei z?)/au
L2          549 (PEI, Z? OR PEI Z?)/AU

=> s l1 and l2
L3           63 L1 AND L2

=> s l1 or l2
L4         5394 L1 OR L2

=> s farnesyltransferase
L5         3582 FARNESYLTRANSFERASE

=> s l3 and l5
L6            6 L3 AND L5

=> duplicate remove l6
DUPLICATE PREFERENCE IS 'MEDLINE, AGRICOLA, CABA, CAPLUS, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L6
L7             2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)

=> d l7 1-2 bib

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2000:227745  CAPLUS
DN   132:248644
TI   Inhibition of farnesyltransferase activity in plants and
     transgenic plants producing farnesyltransferase inhibitors
IN   Schroeder, Julian I.; Pei, Zhen-Ming
PA   The Regents of the University of California, USA
SO   PCT Int. Appl., 41 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2000018880       A2   20000406      WO 1999-US22510  19990929
```

```
     WO 2000018880     A3   20010913
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9961664        A1   20000417       AU 1999-61664    19990929
PRAI US 1998-102569P   P    19980930
     WO 1999-US22510   W    19990929

L7   ANSWER 2 OF 2     MEDLINE on STN                    DUPLICATE 1
AN   1998438697     MEDLINE
DN   98438697   PubMed ID: 9765153
TI   Role of farnesyltransferase in ABA regulation of guard cell
     anion channels and plant water loss.
CM   Comment in: Science. 1998 Oct 9;282(5387):252-3
AU   Pei Z M; Ghassemian M; Kwak C M; McCourt P; Schroeder J
     I
CS   Department of Biology and Center for Molecular Genetics, University of
     California, San Diego, La Jolla, CA 92093-0116, USA.
SO   SCIENCE, (1998 Oct 9) 282 (5387) 287-90.
     Journal code: 0404511. ISSN: 0036-8075.
CY   United States
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals; Space Life Sciences
EM   199810
ED   Entered STN: 19990106
     Last Updated on STN: 20030128
     Entered Medline: 19981026


=> d his

     (FILE 'HOME' ENTERED AT 13:19:35 ON 17 DEC 2003)

     FILE 'MEDLINE, AGRICOLA, CABA, CAPLUS, BIOSIS, BIOTECHNO, USPATFULL'
     ENTERED AT 13:20:45 ON 17 DEC 2003
L1         4908 S (SCHROEDER, J? OR SCHROEDER J?)/AU
L2          549 S (PEI, Z? OR PEI Z?)/AU
L3           63 S L1 AND L2
L4         5394 S L1 OR L2
L5         3582 S FARNESYLTRANSFERASE
L6            6 S L3 AND L5
L7            2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)

=> s l4 not l3
L8         5331 L4 NOT L3

=> s l8and l5
MISSING OPERATOR L8AND L5
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l8 and l5
L9            7 L8 AND L5

=> duplicate remove l9
DUPLICATE PREFERENCE IS 'MEDLINE, AGRICOLA, CABA, CAPLUS, BIOSIS, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L9
```

L10 3 DUPLICATE REMOVE L9 (4 DUPLICATES REMOVED)

=> d l10 1-3 bib

L10 ANSWER 1 OF 3 USPATFULL on STN
AN 2002:345481 USPATFULL
TI Modulation of abscisic acid signal transduction in plants
IN **Schroeder, Julian**, La Jolla, CA, UNITED STATES
Huguovieux, Veronique, La Jolla, CA, UNITED STATES
Kwak, June M., San Diego, CA, UNITED STATES
PA The Regents of the University of California, Oakland, CA, UNITED STATES, 94607-5200 (U.S. corporation)
PI US 2002199219 A1 20021226
AI US 2001-882986 A1 20010614 (9)
PRAI US 2000-212068P 20000614 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 3 MEDLINE on STN DUPLICATE 1
AN 2002374012 MEDLINE
DN 22115185 PubMed ID: 12119381
TI Hypersensitivity of abscisic acid-induced cytosolic calcium increases in the Arabidopsis **farnesyltransferase** mutant era1-2.
AU Allen Gethyn J; Murata Yoshiyuki; Chu Sarah P; Nafisi Majse; **Schroeder Julian I**
CS Cell and Developmental Biology Section, Division of Biology and Center for Molecular Genetics, University of California, San Diego, La Jolla, California 92093-0116, USA.
NC 1P42ES10337 (NIEHS)
GM60396 (NIGMS)
SO PLANT CELL, (2002 Jul) 14 (7) 1649-62.
Journal code: 9208688. ISSN: 1040-4651.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200210
ED Entered STN: 20020717
Last Updated on STN: 20030128
Entered Medline: 20021028

L10 ANSWER 3 OF 3 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1996:256962 BIOSIS
DN PREV199698813091
TI Stable expression of a 5' 400 bp anti-sense of the beta subunit of **farnesyltransferase** in human lung carcinoma blocks oncogenic signaling in vitro and in vivo.
AU Sun, J.; **Pei, Z.**; Sebti, S. M.
CS Univ. Pittsburgh, Pittsburgh, PA 15261, USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (1996) Vol. 37, No. 0, pp. 419.
Meeting Info.: 87th Annual Meeting of the American Association for Cancer Research. Washington, D.C., USA. April 20-24, 1996.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English

```
ED   Entered STN: 31 May 1996
     Last Updated on STN: 11 Jul 1996


=> d his

     (FILE 'HOME' ENTERED AT 13:19:35 ON 17 DEC 2003)

     FILE 'MEDLINE, AGRICOLA, CABA, CAPLUS, BIOSIS, BIOTECHNO, USPATFULL'
     ENTERED AT 13:20:45 ON 17 DEC 2003
L1         4908 S (SCHROEDER, J? OR SCHROEDER J?)/AU
L2          549 S (PEI, Z? OR PEI Z?)/AU
L3           63 S L1 AND L2
L4         5394 S L1 OR L2
L5         3582 S FARNESYLTRANSFERASE
L6            6 S L3 AND L5
L7            2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)
L8         5331 S L4 NOT L3
L9            7 S L8 AND L5
L10           3 DUPLICATE REMOVE L9 (4 DUPLICATES REMOVED)

=> s l5 and plant
L11         186 L5 AND PLANT

=> s l11 not l4
L12         175 L11 NOT L4

=> s l12 and (inhibitor or inhibition)
L13         109 L12 AND (INHIBITOR OR INHIBITION)

=> s l13 and (transformed or transgenic)
L14          70 L13 AND (TRANSFORMED OR TRANSGENIC)

=> duplicate remove l14
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, BIOTECHNO, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L14
L15           66 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)

=> d l15 1-10 ti

L15  ANSWER 1 OF 66  USPATFULL on STN
TI     Methods for generating, selecting, and identifying compounds which bind
       a target molecule

L15  ANSWER 2 OF 66  USPATFULL on STN
TI     Method of identifying conformation-sensitive binding peptides and uses
       thereof

L15  ANSWER 3 OF 66  USPATFULL on STN
TI     Dehydroascorbate reductase ("DHAR") genes and their uses

L15  ANSWER 4 OF 66  USPATFULL on STN
TI     Transgenic plants with enhanced stress tolerance

L15  ANSWER 5 OF 66  USPATFULL on STN
TI     CaaX prenyl protease nucleic acids and polypeptides and methods of use
       thereof

L15  ANSWER 6 OF 66  USPATFULL on STN
TI     Yeast cells engineered to produce pheromone system protein surrogates
       and uses therefor

L15  ANSWER 7 OF 66  USPATFULL on STN
TI     Nck SH3 binding peptides
```

```
L15  ANSWER 8 OF 66  USPATFULL on STN
TI     Method for inhibition of viral infection

L15  ANSWER 9 OF 66  USPATFULL on STN
TI     Method of modifying plant characters by the targeted
       expression of a cell cycle control protein

L15  ANSWER 10 OF 66  USPATFULL on STN
TI     Methods and compositions for diagnosing and treating rheumatoid
       arthritis


=> s farnesyltransferase(w)inhibitor OR farnesyltransferase(s)inhibition
L16        1630 FARNESYLTRANSFERASE(W) INHIBITOR OR FARNESYLTRANSFERASE(S) INHIB
                ITION

=> d his

     (FILE 'HOME' ENTERED AT 13:19:35 ON 17 DEC 2003)

     FILE 'MEDLINE, AGRICOLA, CABA, CAPLUS, BIOSIS, BIOTECHNO, USPATFULL'
     ENTERED AT 13:20:45 ON 17 DEC 2003
L1          4908 S (SCHROEDER, J? OR SCHROEDER J?)/AU
L2           549 S (PEI, Z? OR PEI Z?)/AU
L3            63 S L1 AND L2
L4          5394 S L1 OR L2
L5          3582 S FARNESYLTRANSFERASE
L6             6 S L3 AND L5
L7             2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)
L8          5331 S L4 NOT L3
L9             7 S L8 AND L5
L10            3 DUPLICATE REMOVE L9 (4 DUPLICATES REMOVED)
L11          186 S L5 AND PLANT
L12          175 S L11 NOT L4
L13          109 S L12 AND (INHIBITOR OR INHIBITION)
L14           70 S L13 AND (TRANSFORMED OR TRANSGENIC)
L15           66 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)
L16         1630 S FARNESYLTRANSFERASE(W)INHIBITOR OR FARNESYLTRANSFERASE(S)INHI

=> s l14 and l16
L17          30 L14 AND L16

=> duplicate remove l17
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, BIOTECHNO, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L17
L18           26 DUPLICATE REMOVE L17 (4 DUPLICATES REMOVED)

=> d l18 1-10 ti

L18  ANSWER 1 OF 26  USPATFULL on STN
TI     Yeast cells engineered to produce pheromone system protein surrogates
       and uses therefor

L18  ANSWER 2 OF 26  USPATFULL on STN
TI     Method for inhibition of viral infection

L18  ANSWER 3 OF 26  USPATFULL on STN
TI     Yeast cells engineered to produce pheromone system protein surrogates,
       and uses therefor

L18  ANSWER 4 OF 26  USPATFULL on STN
TI     Inhibitors of protein isoprenyl transferases
```

L18 ANSWER 5 OF 26 USPATFULL on STN
TI Bax degradation involvement in tumor survival and progression

L18 ANSWER 6 OF 26 USPATFULL on STN
TI Farnesyl-protein transferase inhibitors

L18 ANSWER 7 OF 26 USPATFULL on STN
TI Human RCE1

L18 ANSWER 8 OF 26 USPATFULL on STN
TI Inhibitors of protein isoprenyl transferases

L18 ANSWER 9 OF 26 USPATFULL on STN
TI Inhibitors of protein isoprenyl transferases

L18 ANSWER 10 OF 26 USPATFULL on STN
TI Farnesyl-protein transferase inhibitors

=> d l18 2 kwic

L18 ANSWER 2 OF 26 USPATFULL on STN
TI Method for **inhibition** of viral infection
AB The invention is directed to inhibiting viral morphogenesis and viral infection. In particular, it concerns effecting such **inhibition** by inhibiting the prenylation or post prenylation reactions of a viral or host protein.
SUMM [0003] The invention is directed to inhibiting viral morphogenesis and viral infection. In particular, it concerns effecting such **inhibition** by inhibiting the prenylation or post prenylation reactions of a viral or host protein.
SUMM . . . of hepatitis A virus (HAV), hepatitis C virus (HCV), herpes simplex virus (HSV), cytomegalovirus (CMV), varicella-zoster virus (VZV), influenza virus, **plant** viruses such as tobacco mosaic satellite virus (TMSV) and barley stripe mosaic virus (BSMV), the core antigen of hepatitis B. . . to play an important role in the development of AIDS. (Kesstler, H. W. III, et al. Cell (1991) 65:651-662. Accordingly, **inhibition** of the prenylation of these target proteins or the post-prenylation reactions thereof is claimed to be inhibitory to the progress. . .
SUMM . . . cells to halt the viral infection. Such cells may be in culture or may be contained in an animal or **plant** subject.
SUMM . . . "XXCX" (SEQ ID NO: 4), or "XXXC" (SEQ ID NO: 5) box as it occurs in said viral protein, an **inhibitor** of a prenyl transferase, an **inhibitor** of an enzyme included in the pathway of a prenyl lipid synthesis from mevalonate, a mimic of a prenyl group, an **inhibitor** of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX. . . following prenylation, or a protease that removes a C-terminal domain of the prenylated protein including the entire CXXX box, an **inhibitor** of prenyl cysteine methyltransferase, and a combination thereof. Exemplary combination includes a combination of lovastatin, an **inhibitor** of an enzyme included in the pathway of a prenyl lipid synthesis from mevalonate, and 3-allylfarnesol, an **inhibitor** of protein **farnesyltransferase** (Mattingly et al., J. Pharmacol. Exp. Ther., 303(1):74-81 (2002)). Preferably, the agent is administered with a pharmaceutically acceptable carrier or. . .
SUMM [0013] In a specific embodiment, the agent is an **inhibitor** of an enzyme along the pathway of prenyl lipid synthesis from mevalonate i.e., one of the enzymes involved in the. . .
SUMM . . . donor in a functional prenylation reaction. In one aspect, "a mimic of a prenyl group" can behave as a competitive **inhibitor** of a prenyl group donor in a prenylation reaction. Such a competitive **inhibitor** is disclosed in Pompliano et al., Biochemistry,

31:3800-3807 (1992). Pompliano et al. showed that two nonhydrolyzable analogues of farnesyl diphosphate,. . .

SUMM . . . However, it should be noted that the above description of a mimic of a prenyl group behaving as a competitive **inhibitor** in a prenylation reaction is for illustration only. The meaning of the mimic of a prenyl group should not be limited to such competitive **inhibitor** because the mimic may block the normal prenylation through other mechanism(s). For example, a prenyl group may be modified so. . .

SUMM . . . Biochem. Biophys. Res. Commun., 232(2):478-81 (1997)), 2-diazo-3,3,3-trifluoropropionyloxy-farnesyl diphosphate (DATFP-FPP) (Bukhtiyarov et al., J. Biol. Chem., 270(32):19035-40 (1995)), 1-phosphono-(E,E,E)-geranylgeraniol, a dead-end **inhibitor** for GGPP (Stirtan and Poulter, Biochemistry, 36(15):4552-7 (1997)), Cbz-His-Tyr-Ser(OBn)TrpNH2 and Cbz-HisTyr (OP042-)-Ser(OBn)TrpNH2 (Scholten et al., J. Biol. Chem., 272(29):18077-81 (1997)). . .

SUMM [0017] In still another specific embodiment, the agent is an **inhibitor** of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX. . .

SUMM [0018] In yet another specific embodiment, the agent is an **inhibitor** of prenyl cysteine methyltransferase. Any suitable inhibitors of prenyl cysteine methyltransferase can be used in the present methods. For example,. . .

SUMM [0019] The present methods can be used to treat a viral infection in any suitable subject. Exemplary subjects include animal, **plant**, fungus and bacterium subjects. In a specific embodiment, the subject to be treated is an animal or a **plant**. Preferably, the animal is a mammal, e.g., a human or a non-human primate.

SUMM . . . "XXCX" (SEQ ID NO: 4), or "XXXC" (SEQ ID NO: 5) box as it occurs in said viral protein, an **inhibitor** of a prenyl transferase, an **inhibitor** of an enzyme included in the pathway of a prenyl lipid synthesis from mevalonate, a mimic of a prenyl group, an **inhibitor** of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX. . . XCXX polypeptide following prenylation, or a protease that removes the X residue from the XXCX polypeptide following prenylation, and an **inhibitor** of prenyl cysteine methyltransferase; and b) an instruction for using said agent in treating said viral infection in said subject.

SUMM . . . "XXCX" (SEQ ID NO: 4), or "XXXC" (SEQ ID NO: 5) box as it occurs in said viral protein, an **inhibitor** of a prenyl transferase, an **inhibitor** of an enzyme included in the pathway of a prenyl lipid synthesis from mevalonate, a mimic of a prenyl group, an **inhibitor** of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX. . . XCXX polypeptide following prenylation, or a protease that removes the X residue from the XXCX polypeptide following prenylation, and an **inhibitor** of prenyl cysteine methyltransferase. Exemplary viral life cycle events include viral morphogenesis (which may include formation or assembly of the. . .

DRWD [0031] FIGS. 9A-D illustrate in vivo treatment of hepatitis delta virus (HDV) with the prenylation inhibitors FTI-277 and FTI-2153. HBV-**transgenic** mice were inoculated by hydrodynamic transfection to initiate authentic HDV genome replication. Mice were treated for one week by IP. . .

DETD [0039] As used herein, "**plant**" refers to any of various photosynthetic, eucaryotic multi-cellular organisms of the kingdom Plantae, characteristically producing embryos, containing chloroplasts, having cellulose. . .

DETD . . . different effects on genome replication. The small form is required for replication, whereas the large form is a potent trans-dominant **inhibitor** (10, 11).

DETD . . . nature of the COOH-terminal amino acid; Pro (P), which enhances genome replication (20), is replaced by Gln (Q), resulting in

inhibition of genome replication. The second effect is the creation of a target prenylation site (CRPQ), C, cysteine; R, arginine; P,. . .

DETD . . . Thus, the first effect is the conversion of an enhancer of genome replication (small delta antigen) into a potent trans-dominant **inhibitor** (large delta antigen) (10, 11). This dramatic difference in function appears to be determined solely by the nature of the. . .

DETD . . . including drugs that inhibit enzymes along the prenylation pathway, and CXXX box analogs. Both therapies have been considered for the **inhibition** of ras-mediated oncogenic transformation (24). Tetrapeptides that correspond to the CXXX box of p21 Ha-Ras inhibit prenylation of p21 Ha-Ras. . . L genomes require a source of small delta antigen for replication (19, 27) but, once replicated, produce a potent trans-dominant **inhibitor** of further replication, a therapeutically administered L genome DIP could be specific for infected cells, as well as possess an. . .

DETD [0074] Accordingly, new approaches to antiviral therapy and **inhibition** of viral morphogenesis focus on **inhibition** of the prenylation of, or post-prenylation reactions of, at least one viral protein. This may be effected by contacting cells. . . the surroundings of the cysteine residue to be prenylated. For example, Reiss, Y., et al. Cell (1990) 62:81-88 report prenylation **inhibition** by C-A-A-X (SEQ ID NO: 7) tetrapeptides. As set forth above, the cysteine residue to be prenylated is generally found. . .

DETD [0078] The foregoing assay, of course, requires that the **inhibitor** interfere with the prenylation system for large delta antigen or for any other prenylation-controlled secreted protein used in the assay.. . .

DETD . . . identified by one of the variations of the above described assay are expected to find use not only in the **inhibition** of viruses, but also in other processes or disease states--including but not limited to cancer--in which a prenylated protein is. . .

DETD . . . C-terminus. An illustrative list of such proteins includes, for example, specific proteins of HAV, HCV, HSV, CMV, VZV, influenza virus, **plant** viruses such as tobacco mosaic satellite virus and barley stripe mosaic virus, core antigen of hepatitis B virus and the. . .

DETD . . . such as a mammalian subject or in particular a human or other primate subject, the agent used for the prenylation **inhibition** is generally introduced as a pharmaceutical formulation. Suitable formulations depending on the nature of the agent chosen may be found. . . also be used as active ingredients. For administration to plants, formulations which are capable of conducting the active ingredients into **plant** cells are used as carriers.

DETD [0097] The following experiments demonstrate that **inhibition** of prenylation of viral proteins in vivo and/or in vitro can inhibit or retard reproduction of three representative viruses: hepatitis. . .

DETD [0110] **Inhibition** of HDV Virion Production

DETD [0111] In Vitro **Inhibition**

DETD [0112] Experiments were conducted to demonstrate that FTI-277, a prenylation **inhibitor**, can effectively inhibit the production of HDV virions at a concentration that does not significantly affect general protein synthesis and. . .

DETD [0115] FTI-277, a prenylation **inhibitor**, was tested for its ability to inhibit HDV virion production. As shown in FIG. 7, while in the absence of. . .

DETD [0116] Taken together, the above results demonstrate that pharmacological **inhibition** of prenylation can interfere with virus particle production. Furthermore, compounds like FTI-277, which inhibit prenylation, represent a novel class of. . .

DETD [0117] In Vivo **Inhibition**

DETD [0119] HBV-**transgenic** mice were inoculated by hydrodynamic transfection to initiate authentic HDV genome replication. Mice were treated for one week by IP. . .

DETD . . . the above results demonstrate that the prenylation inhibitors

FTI-277 and FTI-2153 can effectively inhibit HDV virion production in vivo. This **inhibition** is not associated with, and cannot be explained by, non-specific toxicity in the testing animals.

DETD [0122] **Inhibition** of Vaccinia Virus Production

DETD . . . 37.degree. C. in CV-1 medium containing vehicle (DMSO) alone, or vehicle plus an equimolar 10 micromolar mixture of FTI-2153 (a **farnesyltransferase inhibitor**) and GGTI-2166 (a geranylgeranyltransferase **inhibitor**) (Sun et al., Cancer Res., 59(19):4919-26 (1999)). On day 2, the cells were fixed with crystal violet to permit detection. . .

DETD . . . recently found that specific mutation of the COOH-terminal Gln of large delta antigen to Pro converted the protein from an **inhibitor** to an enhancer of genome replication (20).

CLM What is claimed is:

. . . "XXCX" (SEQ ID NO: 4), or "XXXC" (SEQ ID NO: 5) box as it occurs in said viral protein, an **inhibitor** of a prenyl transferase, an **inhibitor** of an enzyme included in the pathway of a prenyl lipid synthesis from mevalonate, a mimic of a prenyl group, an **inhibitor** of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX. . . following prenylation, or a protease that removes a C-terminal domain of the prenylated protein including the entire CXXX box, an **inhibitor** of prenyl cysteine methyltransferase, and a combination thereof.

2. The method of claim 1, wherein said agent is an **inhibitor** of an enzyme along the pathway of prenyl lipid synthesis from mevalonate.

4. The method of claim 1, wherein said agent is an **inhibitor** of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX. . .

5. The method of claim 1, wherein said agent is an **inhibitor** of prenyl cysteine methyltransferase.

6. The method of claim 1, wherein said subject is an animal or a **plant**.

19. A kit to treat a viral infection in a subject via inhibiting the prenylation or a post-prenylation reaction of. . . "XXCX" (SEQ ID NO: 4), or "XXXC" (SEQ ID NO: 5) box as it occurs in said viral protein, an **inhibitor** of a prenyl transferase, an **inhibitor** of an enzyme included in the pathway of a prenyl lipid synthesis from mevalonate, a mimic of a prenyl group, an **inhibitor** of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX. . . following prenylation, or a protease that removes a C-terminal domain of the prenylated protein including the entire CXXX box, an **inhibitor** of prenyl cysteine methyltransferase, and a combination thereof; and b) an instruction for using said agent in treating said viral. . .

. . . "XXCX" (SEQ ID NO: 4), or "XXXC" (SEQ ID NO: 5) box as it occurs in said viral protein, an **inhibitor** of a prenyl transferase, an **inhibitor** of an enzyme included in the pathway of a prenyl lipid synthesis from mevalonate, a mimic of a prenyl group, an **inhibitor** of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX. . . following prenylation, or a protease that removes a C-terminal domain of the prenylated protein including the entire CXXX box, an **inhibitor** of prenyl cysteine methyltransferase, and a combination thereof.

=> d his

```
      (FILE 'HOME' ENTERED AT 13:19:35 ON 17 DEC 2003)

      FILE 'MEDLINE, AGRICOLA, CABA, CAPLUS, BIOSIS, BIOTECHNO, USPATFULL'
      ENTERED AT 13:20:45 ON 17 DEC 2003
L1          4908 S (SCHROEDER, J? OR SCHROEDER J?)/AU
L2           549 S (PEI, Z? OR PEI Z?)/AU
L3            63 S L1 AND L2
L4          5394 S L1 OR L2
L5          3582 S FARNESYLTRANSFERASE
L6             6 S L3 AND L5
L7             2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)
L8          5331 S L4 NOT L3
L9             7 S L8 AND L5
L10            3 DUPLICATE REMOVE L9 (4 DUPLICATES REMOVED)
L11          186 S L5 AND PLANT
L12          175 S L11 NOT L4
L13          109 S L12 AND (INHIBITOR OR INHIBITION)
L14           70 S L13 AND (TRANSFORMED OR TRANSGENIC)
L15           66 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)
L16         1630 S FARNESYLTRANSFERASE(W)INHIBITOR OR FARNESYLTRANSFERASE(S)INHI
L17           30 S L14 AND L16
L18           26 DUPLICATE REMOVE L17 (4 DUPLICATES REMOVED)

=> s l18 and guard(s)cell
L19            0 L18 AND GUARD(S) CELL

=> d l18 4,5,6,10 bib

L18  ANSWER 4 OF 26  USPATFULL on STN
AN     2002:338225  USPATFULL
TI     Inhibitors of protein isoprenyl transferases
IN     Sebti, Said M., Tampa, FL, UNITED STATES
       Hamilton, Andrew D., Guilford, CT, UNITED STATES
       Augeri, David J., Kenosha, WI, UNITED STATES
       Barr, Kenneth J., Chicago, IL, UNITED STATES
       Donner, Greg B., Mundelein, IL, UNITED STATES
       Fakhoury, Stephen A., Mundelein, IL, UNITED STATES
       O'Connor, Stephen J., Wilmette, IL, UNITED STATES
       Rosenberg, Saul H., Grayslake, IL, UNITED STATES
       Shen, Wang, Gurnee, IL, UNITED STATES
       Szczepankiewicz, Bruce G., Lindenhurst, IL, UNITED STATES
       Gunawardana, Indrani W., Libertyville, IL, UNITED STATES
PA     University of Pittsburgh, Pittsburgh, PA, UNITED STATES (U.S.
       corporation)
PI     US 2002193596      A1   20021219
AI     US 2001-984411     A1   20011030 (9)
RLI    Continuation-in-part of Ser. No. US 1997-852858, filed on 7 May 1997,
       ABANDONED Continuation-in-part of Ser. No. US 1996-740909, filed on 5
       Nov 1996, ABANDONED
PRAI   US 1995-7247P       19951106 (60)
DT     Utility
FS     APPLICATION
LREP   Pillsbury Winthrop LLP, Intellectual Property Group, 1600 Tysons
       Boulevard, McLean, VA, 22102
CLMN   Number of Claims: 14
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 16873
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18  ANSWER 5 OF 26  USPATFULL on STN
AN     2002:191556  USPATFULL
TI     Bax degradation involvement in tumor survival and progression
IN     Dou, Ping, Tampa, FL, UNITED STATES
       Li, Benyi, Houston, TX, UNITED STATES
```

PI US 2002102621 A1 20020801
AI US 2001-799253 A1 20010305 (9)
PRAI US 2000-186895P 20000303 (60)
DT Utility
FS APPLICATION
LREP Amy E. Rinaldo, Kohn & Associates, Suite 410, 30500 Northwestern Hwy., Farmington Hills, MI, 48334
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 6 OF 26 USPATFULL on STN
AN 2002:194883 USPATFULL
TI Farnesyl-protein transferase inhibitors
IN Shaikenov, Tattym E., Almaty, KAZAKHSTAN
Adekenov, Sergazy M., Karaganda, KAZAKHSTAN
PA International Phytochemistry Research Labs, Ltd., Virginia Beach, VA, United States (U.S. corporation)
PI US 6429203 B1 20020806
AI US 2000-551016 20000418 (9)
RLI Continuation of Ser. No. US 1998-30300, filed on 25 Feb 1998, now patented, Pat. No. US 6051565 Continuation-in-part of Ser. No. US 1997-934228, filed on 19 Sep 1997 Continuation-in-part of Ser. No. US 1997-934229, filed on 19 Sep 1997, now patented, Pat. No. US 5902809 Continuation-in-part of Ser. No. US 1997-934471, filed on 19 Sep 1997
PRAI US 1997-51681P 19970730 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Solola, T. A.
LREP Matney, Jr., W. Jackson, Milbank, Tweed, Hadley & McCloy LLP
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 10 OF 26 USPATFULL on STN
AN 2001:121501 USPATFULL
TI Farnesyl-protein transferase inhibitors
IN Shaikenov, Tattym E., Almaty, Kazakhstan
Adekenov, Sergazy M., Karaganda, Kazakhstan
PA International Phytochemistry Research Labs, Ltd., Virginia Beach, VA, United States (U.S. corporation)
PI US 6268394 B1 20010731
AI US 1999-360832 19990726 (9)
RLI Division of Ser. No. US 1998-30300, filed on 25 Feb 1998, now patented, Pat. No. US 6051565 Continuation-in-part of Ser. No. US 1997-934228, filed on 19 Sep 1997, now abandoned Continuation-in-part of Ser. No. US 1997-934229, filed on 19 Sep 1997, now patented, Pat. No. US 5902809 Continuation-in-part of Ser. No. US 1997-934471, filed on 19 Sep 1997
PRAI KZ 1997-970397 19970426
US 1997-51681P 19970703 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: McKane, Joseph K.; Assistant Examiner: Solola, Taofiq A.
LREP Matney, Jr., W. JacksonMilbank, Tweed, Hadley & McCloy LLP
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1452
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l18 11-20 ti

L18 ANSWER 11 OF 26 USPATFULL on STN
TI Farnesyl-protein transferase inhibitors

L18 ANSWER 12 OF 26 USPATFULL on STN
TI Inhibitors of protein isoprenyl transferases

L18 ANSWER 13 OF 26 USPATFULL on STN
TI Inhibitors of protein isoprenyl transferases

L18 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1
TI Arglabin-DMA, a **plant** derived sesquiterpene, inhibits **farnesyltransferase**

L18 ANSWER 15 OF 26 USPATFULL on STN
TI Human RCE1

L18 ANSWER 16 OF 26 USPATFULL on STN
TI Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor

L18 ANSWER 17 OF 26 USPATFULL on STN
TI Methods and compositions for the identification, characterization and **inhibition** of **farnesyltransferase**

L18 ANSWER 18 OF 26 USPATFULL on STN
TI Farnesyl-protein transferase inhibitors

L18 ANSWER 19 OF 26 MEDLINE on STN DUPLICATE 2
TI TAN-1813, a novel Ras-**farnesyltransferase inhibitor** produced by Phoma sp. taxonomy, fermentation, isolation and biological activities in vitro and in vivo.

L18 ANSWER 20 OF 26 USPATFULL on STN
TI Functional expression of mammalian adenylyl cyclase in yeast

=> d l18 17,19 bib

L18 ANSWER 17 OF 26 USPATFULL on STN
AN 2000:84258 USPATFULL
TI Methods and compositions for the identification, characterization and **inhibition** of **farnesyltransferase**
IN Brown, Michael S., Dallas, TX, United States
Goldstein, Joseph L., Dallas, TX, United States
Reiss, Yuval, Dallas, TX, United States
Marsters, Jim, Oakland, CA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6083917 20000704
AI US 1992-935087 19920824 (7)
RLI Continuation-in-part of Ser. No. US 822011
DT Utility
FS Granted
EXNAM Primary Examiner: Davenport, Avis M.
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 34 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 3386
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 19 OF 26 MEDLINE on STN DUPLICATE 2
AN 2001056249 MEDLINE

DN 20530182 PubMed ID: 11079798
TI TAN-1813, a novel Ras-**farnesyltransferase inhibitor** produced by Phoma sp. taxonomy, fermentation, isolation and biological activities in vitro and in vivo.
AU Ishii T; Hayashi K; Hida T; Yamamoto Y; Nozaki Y
CS Pharmaceutical Discovery Research Division, Takeda Chemical Industries, Ltd., Tsukuba, Ibaraki, Japan.
SO JOURNAL OF ANTIBIOTICS, (2000 Aug) 53 (8) 765-78.
Journal code: 0151115. ISSN: 0021-8820.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200012
ED Entered STN: 20010322
Last Updated on STN: 20020924
Entered Medline: 20001215

=> d l18 21-26 ti

L18 ANSWER 21 OF 26 USPATFULL on STN
TI Methods for the identification of **farnesyltransferase** inhibitors

L18 ANSWER 22 OF 26 USPATFULL on STN
TI Yeast cells engineered to produce pheromone system protein surrogates and uses therefor

L18 ANSWER 23 OF 26 USPATFULL on STN
TI Inhibitors of squalene synthase and protein **farnesyltransferase**

L18 ANSWER 24 OF 26 USPATFULL on STN
TI Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor

L18 ANSWER 25 OF 26 USPATFULL on STN
TI Inhibitors of squalene synthetase and protein **farnesyltransferase**

L18 ANSWER 26 OF 26 USPATFULL on STN
TI Inhibitors of protein **farnesyltransferase** and squalene synthase

=> d l18 21,23,26 bib

L18 ANSWER 21 OF 26 USPATFULL on STN
AN 1999:121146 USPATFULL
TI Methods for the identification of **farnesyltransferase** inhibitors
IN Brown, Michael S., Dallas, TX, United States
Goldstein, Joseph L., Dallas, TX, United States
James, Guy L., Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5962243 19991005
AI US 1995-429964 19950427 (8)
RLI Continuation-in-part of Ser. No. US 1993-21625, filed on 16 Feb 1993 which is a continuation-in-part of Ser. No. US 1992-822011, filed on 16 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-937893, filed on 22 Dec 1992 which is a continuation of Ser. No. WO 1991-US2650, filed on 18 Apr 1991 which is a continuation-in-part of Ser. No. US 1990-615715, filed on 20 Nov 1990, now patented, Pat. No. US 5141851 which is a continuation-in-part of Ser. No. US 1990-510706,

filed on 18 Apr 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Slobodyansky, Elizabeth
LREP Arnold White & Durkee
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 55 Drawing Figure(s); 42 Drawing Page(s)
LN.CNT 4835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 23 OF 26 USPATFULL on STN
AN 1998:135256 USPATFULL
TI Inhibitors of squalene synthase and protein **farnesyltransferase**
IN Arendsen, David L, Libertyville, IL, United States
Baker, William R., Bellevue, WA, United States
Fakhoury, Stephen A, Mundelein, IL, United States
Fung, Anthony K. L., Gurnee, IL, United States
Garvey, David S., Dover, MA, United States
McClellan, William J., Waukegan, IL, United States
O'Connor, Stephen J., Wilmette, IL, United States
Prasad, Rajnandan N., Vernon Hills, IL, United States
Rockway, Todd W., Grayslake, IL, United States
Rosenberg, Saul H., Grayslake, IL, United States
Stein, Herman H., Highland Park, IL, United States
Shen, Wang, Skokie, IL, United States
Stout, David M., Mettawa, IL, United States
Sullivan, Gerard M., Round Lake Beach, IL, United States
Augeri, David J., Kenosha, WI, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5831115 19981103
AI US 1996-626859 19960411 (8)
RLI Continuation-in-part of Ser. No. US 1995-564524, filed on 29 Nov 1995, now abandoned which is a continuation-in-part of Ser. No. US 1995-426553, filed on 21 Apr 1995, now abandoned And a continuation-in-part of Ser. No. US 1995-428357, filed on 21 Apr 1995, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Killos, Paul J.
LREP Steele, Gregory W., Crowley, Steven R.
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4001
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 26 OF 26 USPATFULL on STN
AN 97:43025 USPATFULL
TI Inhibitors of protein **farnesyltransferase** and squalene synthase
IN Stein, Herman H., Highland Park, IL, United States
Baker, William R., Bellevue, WA, United States
Fung, Anthony K. L., Gurnee, IL, United States
Rosenberg, Saul H., Grayslake, IL, United States
Rockway, Todd W., Grayslake, IL, United States
Fakhoury, Stephen A., Mundelein, IL, United States
Garvey, David S., Waltham, MA, United States
Donner, B. Gregory, Mundelein, IL, United States
McClellan, William J., Waukegan, IL, United States
O'Connor, Stephen J., Wilmette, IL, United States
Prasad, Rajnandan, Vernon Hills, IL, United States
Shen, Wang, Skokie, IL, United States
Sullivan, Gerard M., Round Lake Beach, IL, United States

```
PA      Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI      US 5631401              19970520
AI      US 1995-378334          19950124 (8)
RLI     Continuation-in-part of Ser. No. US 1994-194366, filed on 9 Feb 1994,
        now abandoned
DT      Utility
FS      Granted
EXNAM   Primary Examiner: Geist, Gary; Assistant Examiner: Frazier, Barbara S.
LREP    Steele, Gregory W., Crowley, Steven R.
CLMN    Number of Claims: 14
ECL     Exemplary Claim: 1
DRWN    No Drawings
LN.CNT 4493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 13:19:35 ON 17 DEC 2003)

     FILE 'MEDLINE, AGRICOLA, CABA, CAPLUS, BIOSIS, BIOTECHNO, USPATFULL'
     ENTERED AT 13:20:45 ON 17 DEC 2003
L1          4908 S (SCHROEDER, J? OR SCHROEDER J?)/AU
L2           549 S (PEI, Z? OR PEI Z?)/AU
L3            63 S L1 AND L2
L4          5394 S L1 OR L2
L5          3582 S FARNESYLTRANSFERASE
L6             6 S L3 AND L5
L7             2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)
L8          5331 S L4 NOT L3
L9             7 S L8 AND L5
L10            3 DUPLICATE REMOVE L9 (4 DUPLICATES REMOVED)
L11          186 S L5 AND PLANT
L12          175 S L11 NOT L4
L13          109 S L12 AND (INHIBITOR OR INHIBITION)
L14           70 S L13 AND (TRANSFORMED OR TRANSGENIC)
L15           66 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)
L16         1630 S FARNESYLTRANSFERASE(W)INHIBITOR OR FARNESYLTRANSFERASE(S)INHI
L17           30 S L14 AND L16
L18           26 DUPLICATE REMOVE L17 (4 DUPLICATES REMOVED)
L19            0 S L18 AND GUARD(S)CELL

=> s l5 and guard(w)cell
L20           15 L5 AND GUARD(W) CELL

=> s l20 not l4
L21            3 L20 NOT L4

=> duplicate remove l21
DUPLICATE PREFERENCE IS 'CAPLUS, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L21
L22            3 DUPLICATE REMOVE L21 (0 DUPLICATES REMOVED)

=> d l22 1-3 ti

L22  ANSWER 1 OF 3  USPATFULL on STN
TI     Transgenic plants with enhanced stress tolerance

L22  ANSWER 2 OF 3  USPATFULL on STN
TI     CaaX prenyl protease nucleic acids and polypeptides and methods of use
       thereof

L22  ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
TI   Transgenic plants with improved stress tolerance or delayed senescence
```

expressing antisense farnesyl transferase nucleic acids

=> d l22 1-3 bib

L22 ANSWER 1 OF 3 USPATFULL on STN
AN 2003:290111 USPATFULL
TI Transgenic plants with enhanced stress tolerance
IN Kim, Soo Young, Kwangsan-Gu, KOREA, REPUBLIC OF
Choi, Hyung In, Mokpo-Shi, KOREA, REPUBLIC OF
Kang, Joung-Youn, Buk-Gu, KOREA, REPUBLIC OF
Im, Min-Young, Buk-Gu, KOREA, REPUBLIC OF
PI US 2003204874 A1 20031030
AI US 2002-128456 A1 20020424 (10)
DT Utility
FS APPLICATION
LREP KENYON & KENYON, 1500 K STREET, N.W., SUITE 700, WASHINGTON, DC, 20005
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1163
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 2 OF 3 USPATFULL on STN
AN 2003:290102 USPATFULL
TI CaaX prenyl protease nucleic acids and polypeptides and methods of use thereof
IN Wan, Jiangxin, Kingston, CANADA
Huang, Yafan, Kingston, CANADA
Melo, Delina Mary-Jane, Inverary, CANADA
Kuzma, Monika Maria, Glenburnie, CANADA
Gilley Sample, Angela Patricia, Inverary, CANADA
PI US 2003204865 A1 20031030
AI US 2002-210760 A1 20020801 (10)
PRAI US 2001-309396P 20010801 (60)
US 2001-337084P 20011204 (60)
DT Utility
FS APPLICATION
LREP Ivor R. Elrifi, Ph.D., Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, P.C., One Financial Center, Boston, MA, 02111
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 6397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:927600 CAPLUS
DN 138:22288
TI Transgenic plants with improved stress tolerance or delayed senescence expressing antisense farnesyl transferase nucleic acids
IN Huang, Yafan; Chalifoux, Maryse; Wang, Yang; Kuzma, Monika D.; Gilley, Angela P.
PA Performance Plants, Inc., Can.
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002097097	A2	20021205	WO 2002-IB3033	20020531

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

```
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
            TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
            CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    US 2003167535     A1   20030904      US 2002-160764   20020531
PRAI US 2001-294766P  P    20010531
    US 2001-348909P   P    20011022


=> d his

    (FILE 'HOME' ENTERED AT 13:19:35 ON 17 DEC 2003)

    FILE 'MEDLINE, AGRICOLA, CABA, CAPLUS, BIOSIS, BIOTECHNO, USPATFULL'
    ENTERED AT 13:20:45 ON 17 DEC 2003
L1          4908 S (SCHROEDER, J? OR SCHROEDER J?)/AU
L2           549 S (PEI, Z? OR PEI Z?)/AU
L3            63 S L1 AND L2
L4          5394 S L1 OR L2
L5          3582 S FARNESYLTRANSFERASE
L6             6 S L3 AND L5
L7             2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)
L8          5331 S L4 NOT L3
L9             7 S L8 AND L5
L10            3 DUPLICATE REMOVE L9 (4 DUPLICATES REMOVED)
L11          186 S L5 AND PLANT
L12          175 S L11 NOT L4
L13          109 S L12 AND (INHIBITOR OR INHIBITION)
L14           70 S L13 AND (TRANSFORMED OR TRANSGENIC)
L15           66 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)
L16         1630 S FARNESYLTRANSFERASE(W)INHIBITOR OR FARNESYLTRANSFERASE(S)INHI
L17           30 S L14 AND L16
L18           26 DUPLICATE REMOVE L17 (4 DUPLICATES REMOVED)
L19            0 S L18 AND GUARD(S)CELL
L20           15 S L5 AND GUARD(W)CELL
L21            3 S L20 NOT L4
L22            3 DUPLICATE REMOVE L21 (0 DUPLICATES REMOVED)

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               59.18      59.60

STN INTERNATIONAL LOGOFF AT 13:32:04 ON 17 DEC 2003
```